A BMAC injection may reduce pain and improve joint function for some people, particularly those with knee osteoarthritis. However, results vary and research is still developing. This guide looks at what current studies show, where BMAC appears most promising and why realistic expectations matter.

What does the research say?

BMAC stands for bone marrow aspirate concentrate. During treatment, bone marrow is usually collected from the pelvis, processed to concentrate its biological components and then injected into the affected joint or tissue.

The treatment has attracted particular interest for knee osteoarthritis. A 2025 systematic review found that intra-articular BMAC had improved functional outcomes in clinical studies involving people with knee osteoarthritis. However, the researchers also concluded that the ideal indications remain unclear and that conflicting results make it difficult to say BMAC is superior to other orthobiological treatments.

Another systematic review published in 2024 reached a similar conclusion. It found that BMAC injections could provide pain relief and functional improvement for people with knee osteoarthritis, but differences compared with other injection treatments did not clearly exceed clinically important thresholds. The authors called for further research.

So, does a BMAC injection work? The evidence suggests that it can help some patients, but it is not guaranteed to work and it has not been shown consistently to outperform every alternative.

What improvements might patients notice?

When BMAC is successful, patients may experience reduced joint pain, better mobility and an improved ability to complete everyday activities. These changes tend to develop gradually rather than immediately because the treatment is intended to influence the local biological environment rather than simply provide short-term pain relief.

The Regenesis Clinics explains that some patients report gradual improvements in pain, mobility and daily function over several weeks or months following treatment. Mild soreness or swelling can also occur for several days after the procedure.

However, BMAC should not be presented as a guaranteed way to regrow cartilage or reverse severe arthritis. Current evidence is much stronger for improvements in symptoms and function than for claims that the procedure can completely restore damaged joint structures.

This distinction is important. Feeling better after a BMAC injection does not necessarily mean that osteoarthritis has disappeared. The practical goal may instead be to reduce symptoms, improve function and make everyday movement more manageable.

Who is most likely to benefit?

Patient selection appears to be one of the biggest unanswered questions surrounding BMAC. The 2025 systematic review specifically noted that indications for treatment remain unclear, which means researchers are still working to identify which patients are most likely to benefit.

Clinicians may consider BMAC for people with conditions such as knee osteoarthritis, cartilage damage, chronic joint pain and selected tendon or ligament injuries. Patients often explore it after physiotherapy, medication or conventional injections have not provided sufficient relief.

The severity and cause of your symptoms matter. Someone with mild or moderate degenerative changes may have very different treatment options from a person with advanced joint destruction who is already a strong candidate for joint replacement surgery.

Your age, general health, previous treatments and activity goals may also influence the decision. A proper assessment should therefore include your medical history, symptoms and relevant imaging rather than relying on pain levels alone.

How strong is the evidence compared with other treatments?

BMAC is promising, but it remains an evolving treatment. NICE currently identifies intra-articular stem-cell injections for osteoarthritis as an area where further research into clinical and cost effectiveness is needed.

Research comparing BMAC with treatments such as platelet-rich plasma has also produced mixed results. A 2024 network meta-analysis found that PRP produced significant improvements in pain and function for knee osteoarthritis and ranked higher than BMAC in the comparison, although differences between studies and treatment protocols remain important limitations.

That does not mean a BMAC injection has no value. It means patients should be cautious about claims that it is automatically the most advanced or effective option simply because it uses bone marrow.

A responsible clinician should explain what evidence applies to your specific condition, how BMAC compares with alternatives and what outcome would realistically count as a successful result.

So, do BMAC injections really work? Current evidence suggests that they can improve pain and joint function for some patients, particularly those with knee osteoarthritis, but results vary and BMAC has not been proven consistently superior to other regenerative injections. It should therefore be viewed as one potential treatment option rather than a guaranteed solution.

If persistent joint pain continues despite conservative treatment, explore more information about BMAC therapy or contact The Regenesis Clinics for an individual assessment. A specialist can review your symptoms, scans and previous treatments to determine whether BMAC or another approach is more appropriate.